default author photo

Mihaela Lazar

Cantacuzino National Military Medical Institute for Research and Development

SCHOLARLY PAPERS

3

DOWNLOADS

323

TOTAL CITATIONS

1

Scholarly Papers (3)

1.

The Potential Bias Introduced into COVID-19 Vaccine Effectiveness Studies at Primary Care Level Due to the Availability of SARS-CoV-2 Tests in the General Population

Number of pages: 28 Posted: 12 Nov 2024
Epiconcept, Epiconcept, Carlos III Institute of Health - Communicable Diseases Department, National Institute for Public Health and the Environment (RIVM), Semmelweis University, National Institute of Health Doutor Ricardo Jorge, Public Health Agency of Sweden, Croatian Institute of Public Health, Cantacuzino National Military Medical Institute for Research and Development, Consejería de Sanidad - Dirección General de Salud Pública, Robert Koch Institute - Department for Infectious Disease Epidemiology, Sorbonne University - Institut Pierre Louis d'Épidémiologie et de Santé Publique IPLESP, Health Service Executive, Universidad Pública de Navarra - IdiSNA, Navarra Institute for Health Research, NIVEL (Netherlands Institute for Health Services Research), Semmelweis University, National Health Institute Doutor Ricardo Jorge (INSA) - National Influenza Reference Laboratory, Public Health Agency of Sweden, Croatian Institute of Public Health, Cantacuzino National Military Medical Institute for Research and Development, Consejería de Sanidad - Dirección General de Salud Pública, Robert Koch Institute, Université Paris Saclay, Health Service Executive, Instituto de Salud Pública y Laboral de Navarra, National Institute for Public Health and the Environment (RIVM), National Institute for Public Health and the Environment (RIVM), European Centre for Disease Prevention and Control, European Centre for Disease Prevention and Control and Epiconcept
Downloads 112 (630,858)
Citation 1

Abstract:

Loading...

COVID-19, Vaccine effectiveness, Test-negative design, Self-test, Bias, Directed acyclic graph, Simulation

2.

COVID-19 Vaccine Effectiveness against Medically Attended Symptomatic SARS-CoV-2 Infection among Target Groups in Europe, October 2024-January 2025, VEBIS Primary Care Network

Number of pages: 20 Posted: 21 Mar 2025
Epiconcept, National Health Institute Doutor Ricardo Jorge (INSA) - Epidemiology Department, Carlos III Institute of Health - Communicable Diseases Department, Health Protection Surveillance Centre (HPSC), Sorbonne University - Institut Pierre Louis d'Épidémiologie et de Santé Publique IPLESP, Robert Koch Institute, National Institute for Public Health and the Environment (RIVM) - Centre for Infectious Disease Control, Epiconcept, Subdirección General de Epidemiología y Vigilancia de la Salud, Health Service Executive, University of Paris-Saclay - Institut Pasteur, Robert Koch Institute, National Institute for Public Health and the Environment (RIVM) - Centre for Infectious Disease Control, Murcia Regional Health Council-IMIB, University College Dublin (UCD), University of Corsica, Robert Koch Institute - Department for Infectious Disease Epidemiology, NIVEL (Netherlands Institute for Health Services Research), Croatian Institute of Public Health, Semmelweis University, National Health Institute Doutor Ricardo Jorge (INSA) - Epidemiology Department, Universidad Pública de Navarra - IdiSNA, Navarra Institute for Health Research, Cantacuzino National Military Medical Institute for Research and Development, Public Health Agency of Sweden, National Health Institute Doutor Ricardo Jorge (INSA) - Bioinformatics Unit, European Centre for Disease Prevention and Control, European Centre for Disease Prevention and Control and Epiconcept
Downloads 108 (649,907)

Abstract:

Loading...

COVID-19, vaccine effectiveness, SARS-CoV-2, Europe

3.

COVID-19 Vaccine Effectiveness Among Older Adults in 2025/26

Number of pages: 16 Posted: 12 Mar 2026 Last Revised: 20 Mar 2026
Epiconcept, Bruno Kessler Foundation, Carlos III Health Institute, Health Protection Surveillance Centre (HPSC), Sorbonne University - Institut Pierre Louis d'Épidémiologie et de Santé Publique IPLESP, Robert Koch Institute - Department for Infectious Disease Epidemiology, Croatian Institute of Public Health, Semmelweis University, National Institute for Public Health and the Environment (RIVM) - Centre for Infectious Disease Control, National Health Institute Doutor Ricardo Jorge (INSA) - Epidemiology Department, Cantacuzino National Military Medical Institute for Research and Development, Public Health Agency of Sweden, Epiconcept, National Health Institute Doutor Ricardo Jorge (INSA) - Epidemiology Department, Istituto Superiore di Sanità, The Directorate General of Public Health, The Health Service Executive-Health Protection Surveillance Centre (HSE-HPSC), University of Paris-Saclay - Institut Pasteur, Robert Koch Institute - Department for Infectious Disease Epidemiology, Istituto Superiore di Sanità - Department of Infectious Diseases, Consejería de Sanidad - Dirección General de Salud Pública, Instituto de Salud Pública y Laboral de Navarra, The Health Service Executive-Health Protection Surveillance Centre (HSE-HPSC), University of Corsica, Robert Koch Institute, European Centre for Disease Prevention and Control, European Centre for Disease Prevention and Control and Epiconcept
Downloads 103 (674,591)

Abstract:

Loading...

COVID-19, SARS-CoV-2, Vaccine effectiveness, Europe